Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer – A Systematic Review
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations is scattered and limited to mostly retrospective small cohorts, as these patients were usually excluded from clinical trials.